{"id":4286,"date":"2024-10-28T06:30:41","date_gmt":"2024-10-28T10:30:41","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\/"},"modified":"2026-11-04T04:31:02","modified_gmt":"2026-11-04T03:31:02","slug":"gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2024\/10\/28\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\/","title":{"rendered":"GenSight Biologics annonce la publication de m\u00e9ta-analyses d\u00e9montrant une meilleure efficacit\u00e9 du traitement par LUMEVOQ\u00ae chez les patients ND4-NOHL"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Paris, France, le 28 octobre 2024, 7h30 CET<\/strong> \u2013 GenSight Biologics (Euronext\u00a0: SIGHT, ISIN\u00a0: FR0013183985, \u00e9ligible au PEA-PME), soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement et la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour les maladies neurod\u00e9g\u00e9n\u00e9ratives r\u00e9tiniennes et les troubles du syst\u00e8me nerveux central, annonce aujourd&rsquo;hui la publication de m\u00e9ta-analyses comparant l\u2019am\u00e9lioration de la vision parmi les patients atteints de neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL) caus\u00e9e par une mutation du g\u00e8ne mitochondrial<em> MT-ND4<\/em> (<em>ND4-<\/em>NOHL), la mutation la plus fr\u00e9quente et celle pr\u00e9sentant le pronostic le plus d\u00e9favorable<a href=\"#_ftn1\" name=\"_ftnref1\">[1]<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Cet article, publi\u00e9 dans la revue scientifique <em>Survey of Ophthalmology<\/em>, compare pour la premi\u00e8re fois l\u2019efficacit\u00e9 des traitements pour la NOHL, approuv\u00e9s ou en cours de d\u00e9veloppement, sur l\u2019am\u00e9lioration de la vision obtenue chez des patients<em> ND4<\/em>-NOHL. Il compare \u00e9galement ces r\u00e9sultats avec ceux obtenus chez les patients non trait\u00e9s (\u00e9volution naturelle). Ces m\u00e9ta-analyses montrent un \u00ab\u00a0gradient d\u2019efficacit\u00e9\u00a0\u00bb pour les deux crit\u00e8res d\u2019am\u00e9lioration de l\u2019acuit\u00e9 visuelle \u00e9valu\u00e9s dans cet article, la th\u00e9rapie g\u00e9nique LUMEVOQ<sup>\u00ae<\/sup> permettant une r\u00e9cup\u00e9ration visuelle plus \u00e9lev\u00e9e que le traitement par id\u00e9b\u00e9none, et les deux traitements \u00e9tant sup\u00e9rieurs \u00e0 l&rsquo;\u00e9volution naturelle de la maladie.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sur la base du taux de r\u00e9cup\u00e9ration cliniquement pertinente (CRR)<sup>2<\/sup>, qui correspond au taux de r\u00e9ponse commun pour les \u00e9tudes analys\u00e9es dans cet article, la th\u00e9rapie g\u00e9nique LUMEVOQ<sup>\u00ae<\/sup> triple le taux de r\u00e9cup\u00e9ration visuelle pour les patients atteints de NOHL-<em>ND4<\/em> en comparaison \u00e0 l\u2019absence de traitement (\u00e9volution naturelle) et augmente substantiellement le taux de r\u00e9cup\u00e9ration visuelle par rapport au traitement par id\u00e9b\u00e9none.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00ab\u00a0<em>Cette \u00e9tude joue un r\u00f4le tr\u00e8s important pour comparer l&rsquo;efficacit\u00e9 de ces th\u00e9rapies dans l&rsquo;am\u00e9lioration des fonctions visuelles chez les patients ND4-NOHL<\/em>\u00a0\u00bb commente le <strong>Dr. Nancy J. Newman, <\/strong>chaire <em>LeoDelle Jolley<\/em> et professeur d\u2019ophtalmologie et de neurologie \u00e0 l\u2019Emory University School of Medicine d\u2019Atlanta, aux \u00c9tats-Unis, et auteure principale de l&rsquo;article. \u00ab\u00a0<em>Pour la premi\u00e8re fois,<\/em> n<em>ous d\u00e9montrons clairement un gradient d\u2019efficacit\u00e9 pour l&rsquo;am\u00e9lioration visuelle, plus marqu\u00e9 du point de vue de la r\u00e9cup\u00e9ration cliniquement pertinente (CRR) que pour la meilleure acuit\u00e9 visuelle corrig\u00e9e (BCVA) finale, la th\u00e9rapie g\u00e9nique lenadogene permettant d\u2019obtenir une r\u00e9cup\u00e9ration visuelle plus \u00e9lev\u00e9e que celle du traitement par id\u00e9b\u00e9none, et les deux traitements permettant une am\u00e9lioration par rapport \u00e0 l\u2019\u00e9volution naturelle de la maladie\u00a0\u00bb.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L\u2019article constitue une mise \u00e0 jour des <a href=\"https:\/\/www.gensight-biologics.com\/fr\/2024\/03\/12\/nanos-2024-gensight-biologics-annonce-les-premiers-resultats-issus-de-nouvelles-meta-analyses-sur-lamelioration-de-la-vision-obtenue-avec-la-therapie-genique-lumevoq\/\">conclusions ant\u00e9rieures<\/a> pr\u00e9sent\u00e9es lors de la r\u00e9union annuelle 2024 de la North American Neuro-Ophthalmology Society (NANOS). Ainsi, cet article int\u00e8gre les donn\u00e9es de l&rsquo;essai id\u00e9b\u00e9none LEROS r\u00e9cemment publi\u00e9es et \u00e9galement l\u2019\u00e9valuation des valeurs d\u2019acuit\u00e9 visuelle (<em>Best-Corrected Visual Acuity <\/em>ou BCVA) finales pour les trois groupes de patients.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Figure 1. \u00ab\u00a0Gradient d\u2019efficacit\u00e9\u00a0\u00bb\u00a0: r\u00e9cup\u00e9ration visuelle (CRR<a href=\"#_ftn2\" name=\"_ftnref2\">[2]<\/a> versus Nadir<a href=\"#_ftn3\" name=\"_ftnref3\">[3]<\/a>) chez les patients atteints de NOHL <em>ND4<\/em><a href=\"#_ftn4\" name=\"_ftnref4\">[4]<\/a><sup>,<a href=\"#_ftn5\" name=\"_ftnref5\">[5]<\/a><\/sup><\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-12787\" src=\"\/wp-content\/uploads\/2024\/10\/Meta-Analyses-Figure-1-FR-website-500x375.jpg\" alt=\"\" width=\"500\" height=\"375\" \/><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ces m\u00e9ta-analyses constituent l&rsquo;\u00e9valuation la plus exhaustive jamais r\u00e9alis\u00e9e des donn\u00e9es disponibles sur l&rsquo;\u00e9volution naturelle de la maladie chez les patients atteints de perte de vision en lien avec la mutation <em>MT-ND4<\/em> NOHL et chez les patients trait\u00e9s par id\u00e9b\u00e9none. Elle pr\u00e9sente \u00e9galement l&rsquo;ensemble des r\u00e9sultats disponibles sur l\u2019efficacit\u00e9 de la th\u00e9rapie g\u00e9nique lenadogene nolparvovec. La population NOHL-<em>ND4 <\/em>de chaque groupe correspond aux caract\u00e9ristiques d\u00e9mographiques typiques des patients atteints par la maladie. En l\u2019absence de traitement (\u00e9volution naturelle), la plupart des patients NOHL-<em>ND4<\/em> pr\u00e9sentent une r\u00e9duction s\u00e9v\u00e8re et chronique de l&rsquo;acuit\u00e9 visuelle des deux yeux, ce qui r\u00e9duit consid\u00e9rablement leur qualit\u00e9 de vie.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>L\u2019article est disponible en ligne via ce <\/strong><a href=\"https:\/\/www.surveyophthalmol.com\/article\/S0039-6257(24)00130-9\/fulltext\"><strong>lien<\/strong><\/a><strong>.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"#_ftnref1\" name=\"_ftn1\">[1]<\/a> Newman et al: <em>J Neuro-Ophthalmol<\/em> <em>2020 Dec<\/em>;40(4):547-557.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"#_ftnref2\" name=\"_ftn2\">[2]<\/a> \u00ab\u00a0r\u00e9cup\u00e9ration cliniquement pertinente\u00a0\u00bb (CRR) d\u00e9signe une am\u00e9lioration de la meilleure acuit\u00e9 visuelle corrig\u00e9e (BCVA) r\u00e9pondant \u00e0 l\u2019une des deux conditions suivantes\u00a0: (1) Am\u00e9lioration de 10 lettres (\u2265 0,2 LogMAR) pour une acuit\u00e9 visuelle \u00ab\u00a0on-chart\u00a0\u00bb initiale. (2) Passage de \u00ab\u00a0off-chart\u00a0\u00bb \u00e0 \u00ab\u00a0on-chart\u00a0\u00bb (\u2264 1,6 LogMAR).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"#_ftnref3\" name=\"_ftn3\">[3]<\/a> Nadir = la pire acuit\u00e9 visuelle enregistr\u00e9e entre la <em>baseline<\/em> (juste avant le traitement) et le point d\u2019int\u00e9r\u00eat dans le temps (moment de l&rsquo;\u00e9valuation).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"#_ftnref4\" name=\"_ftn4\">[4]<\/a> Trois m\u00e9ta-analyses pr\u00e9d\u00e9finies dans un plan d\u2019analyse statistique<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"#_ftnref5\" name=\"_ftn5\">[5]<\/a> Sources des donn\u00e9es\u00a0: Pour l\u2019id\u00e9b\u00e9none et les donn\u00e9es d\u2019\u00e9volution naturelle, revue syst\u00e9matique de la litt\u00e9rature et des rapports cliniques\/r\u00e9glementaires disponibles chez les patients atteints de NOHL <em>ND4<\/em>\u00a0; pour le Lumevoq, toutes les \u00e9tudes de phase\u00a03 (RESCUE\/RESTORE, REVERSE\/RESTORE et REFLECT).<\/p>\n","protected":false},"excerpt":{"rendered":"<ul>\n<li>Les patients trait\u00e9s par la th\u00e9rapie g\u00e9nique LUMEVOQ<sup>\u00ae<\/sup> connaissent une am\u00e9lioration de l\u2019acuit\u00e9 visuelle plus \u00e9lev\u00e9e que les patients trait\u00e9s par id\u00e9b\u00e9none, et les patients sans traitement<\/li>\n<li>Ces m\u00e9ta-analyses constituent l&rsquo;\u00e9valuation la plus compl\u00e8te de l\u2019am\u00e9lioration de la vision jamais r\u00e9alis\u00e9e chez les patients atteints de neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL) avec mutation <em>ND4<\/em><\/li>\n<\/ul>\n","protected":false},"author":4,"featured_media":4288,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[],"news-topic":[73],"news-type":[74,75],"post-year":[111],"class_list":["post-4286","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-communiques-de-presse-financiers","news-topic-gs010-lumevoq","news-type-product-candidates","news-type-clinical","post-year-111"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics annonce la publication de m\u00e9ta-analyses d\u00e9montrant une meilleure efficacit\u00e9 du traitement par LUMEVOQ\u00ae chez les patients ND4-NOHL | GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2024\/10\/28\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics annonce la publication de m\u00e9ta-analyses d\u00e9montrant une meilleure efficacit\u00e9 du traitement par LUMEVOQ\u00ae chez les patients ND4-NOHL | GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Les patients trait\u00e9s par la th\u00e9rapie g\u00e9nique LUMEVOQ\u00ae connaissent une am\u00e9lioration de l\u2019acuit\u00e9 visuelle plus \u00e9lev\u00e9e que les patients trait\u00e9s par id\u00e9b\u00e9none, et les patients sans traitement  Ces m\u00e9ta-analyses constituent l&#039;\u00e9valuation la plus compl\u00e8te de l\u2019am\u00e9lioration de la vision jamais r\u00e9alis\u00e9e chez les patients atteints de neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL) avec mutation ND4\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2024\/10\/28\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-28T10:30:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-04T03:31:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/Meta-Analyses-Figure-1-FR-website.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"851\" \/>\n\t<meta property=\"og:image:height\" content=\"638\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"jbenedicto\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"jbenedicto\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/10\\\/28\\\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/10\\\/28\\\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\\\/\"},\"author\":{\"name\":\"jbenedicto\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/4deb9538eb9b578965a0f75a4939ef0a\"},\"headline\":\"GenSight Biologics annonce la publication de m\u00e9ta-analyses d\u00e9montrant une meilleure efficacit\u00e9 du traitement par LUMEVOQ\u00ae chez les patients ND4-NOHL\",\"datePublished\":\"2024-10-28T10:30:41+00:00\",\"dateModified\":\"2026-11-04T03:31:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/10\\\/28\\\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\\\/\"},\"wordCount\":833,\"publisher\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/10\\\/28\\\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.gensight-biologics.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Meta-Analyses-Figure-1-FR-website.jpg\",\"articleSection\":[\"Communiqu\u00e9 de presse financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/10\\\/28\\\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/10\\\/28\\\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\\\/\",\"name\":\"GenSight Biologics annonce la publication de m\u00e9ta-analyses d\u00e9montrant une meilleure efficacit\u00e9 du traitement par LUMEVOQ\u00ae chez les patients ND4-NOHL | GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/10\\\/28\\\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/10\\\/28\\\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.gensight-biologics.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Meta-Analyses-Figure-1-FR-website.jpg\",\"datePublished\":\"2024-10-28T10:30:41+00:00\",\"dateModified\":\"2026-11-04T03:31:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/10\\\/28\\\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/10\\\/28\\\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/10\\\/28\\\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Meta-Analyses-Figure-1-FR-website.jpg\",\"contentUrl\":\"https:\\\/\\\/www.gensight-biologics.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Meta-Analyses-Figure-1-FR-website.jpg\",\"width\":851,\"height\":638},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2024\\\/10\\\/28\\\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics annonce la publication de m\u00e9ta-analyses d\u00e9montrant une meilleure efficacit\u00e9 du traitement par LUMEVOQ\u00ae chez les patients ND4-NOHL\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#organization\",\"name\":\"GenSight Biologics\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Gensight-Logo-2.jpg\",\"contentUrl\":\"https:\\\/\\\/www.gensight-biologics.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Gensight-Logo-2.jpg\",\"width\":696,\"height\":696,\"caption\":\"GenSight Biologics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/8104807?trk=prof-exp-company-name\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/4deb9538eb9b578965a0f75a4939ef0a\",\"name\":\"jbenedicto\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g\",\"caption\":\"jbenedicto\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics annonce la publication de m\u00e9ta-analyses d\u00e9montrant une meilleure efficacit\u00e9 du traitement par LUMEVOQ\u00ae chez les patients ND4-NOHL | GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2024\/10\/28\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics annonce la publication de m\u00e9ta-analyses d\u00e9montrant une meilleure efficacit\u00e9 du traitement par LUMEVOQ\u00ae chez les patients ND4-NOHL | GenSight Biologics","og_description":"Les patients trait\u00e9s par la th\u00e9rapie g\u00e9nique LUMEVOQ\u00ae connaissent une am\u00e9lioration de l\u2019acuit\u00e9 visuelle plus \u00e9lev\u00e9e que les patients trait\u00e9s par id\u00e9b\u00e9none, et les patients sans traitement  Ces m\u00e9ta-analyses constituent l'\u00e9valuation la plus compl\u00e8te de l\u2019am\u00e9lioration de la vision jamais r\u00e9alis\u00e9e chez les patients atteints de neuropathie optique h\u00e9r\u00e9ditaire de Leber (NOHL) avec mutation ND4","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2024\/10\/28\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\/","og_site_name":"GenSight Biologics","article_published_time":"2024-10-28T10:30:41+00:00","article_modified_time":"2026-11-04T03:31:02+00:00","og_image":[{"width":851,"height":638,"url":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/Meta-Analyses-Figure-1-FR-website.jpg","type":"image\/jpeg"}],"author":"jbenedicto","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"jbenedicto","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/10\/28\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/10\/28\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\/"},"author":{"name":"jbenedicto","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/4deb9538eb9b578965a0f75a4939ef0a"},"headline":"GenSight Biologics annonce la publication de m\u00e9ta-analyses d\u00e9montrant une meilleure efficacit\u00e9 du traitement par LUMEVOQ\u00ae chez les patients ND4-NOHL","datePublished":"2024-10-28T10:30:41+00:00","dateModified":"2026-11-04T03:31:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/10\/28\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\/"},"wordCount":833,"publisher":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/10\/28\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\/#primaryimage"},"thumbnailUrl":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/Meta-Analyses-Figure-1-FR-website.jpg","articleSection":["Communiqu\u00e9 de presse financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/10\/28\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2024\/10\/28\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\/","name":"GenSight Biologics annonce la publication de m\u00e9ta-analyses d\u00e9montrant une meilleure efficacit\u00e9 du traitement par LUMEVOQ\u00ae chez les patients ND4-NOHL | GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/10\/28\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\/#primaryimage"},"image":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/10\/28\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\/#primaryimage"},"thumbnailUrl":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/Meta-Analyses-Figure-1-FR-website.jpg","datePublished":"2024-10-28T10:30:41+00:00","dateModified":"2026-11-04T03:31:02+00:00","breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/10\/28\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2024\/10\/28\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/10\/28\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\/#primaryimage","url":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/Meta-Analyses-Figure-1-FR-website.jpg","contentUrl":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/Meta-Analyses-Figure-1-FR-website.jpg","width":851,"height":638},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2024\/10\/28\/gensight-biologics-annonce-la-publication-de-meta-analyses-demontrant-une-meilleure-efficacite-du-traitement-par-lumevoq-chez-les-patients-nd4-nohl\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics annonce la publication de m\u00e9ta-analyses d\u00e9montrant une meilleure efficacit\u00e9 du traitement par LUMEVOQ\u00ae chez les patients ND4-NOHL"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","publisher":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.gensight-biologics.com\/fr\/#organization","name":"GenSight Biologics","url":"https:\/\/www.gensight-biologics.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/11\/Gensight-Logo-2.jpg","contentUrl":"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/11\/Gensight-Logo-2.jpg","width":696,"height":696,"caption":"GenSight Biologics"},"image":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/8104807?trk=prof-exp-company-name"]},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/4deb9538eb9b578965a0f75a4939ef0a","name":"jbenedicto","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c01e1c29f629dac56455efec1ea9cbd23c254b626dfca256f82e444f534c779?s=96&d=mm&r=g","caption":"jbenedicto"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4286","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=4286"}],"version-history":[{"count":1,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4286\/revisions"}],"predecessor-version":[{"id":10231,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4286\/revisions\/10231"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media\/4288"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=4286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=4286"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=4286"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=4286"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=4286"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=4286"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=4286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}